Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by ...
Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While ...
Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
New Delhi: Pharma major Dr Reddy’s Laboratories (DRL ... Its total operating expenses grew 34.3 per cent to Rs3,021.8 ...
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...